Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

The pharmacogenomics journal - 1 Jan 2018

Li M, Seiser E L, Baldwin R M, Ramirez J, Ratain M J, Innocenti F, Kroetz D L

Abstract excerpt

Neutropenia is a common dose-limiting toxicity associated with irinotecan treatment. Although UGT1A1 variants have been associated with neutropenia, a fraction of neutropenia risk remains unaccounted for. To identify additional genetic markers contributing to variability in irinotecan pharmacokinetics and neutropenia, a regression analysis was performed in 78 irinotecan-treated patients to analyze comprehensively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to ATP-Binding Cassette Transporters

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Irinotecan

Share to Membrane Transport Proteins

Share to Neoplasm Proteins

Share to Neutropenia

Share to Polymorphism, Single Nucleotide

Share to Transcriptional Activation

Source

Open in PubMed Open full text

Identifiers

PMID: 27845419
DOI: 10.1038/tpj.2016.75
PMCID: PMC5432414

Genes

ABCC1
ABCB1
ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.PMID 27845419Read ↗

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.Semantic proximity Read ↗

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.Semantic proximity Read ↗

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.Semantic proximity Read ↗

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.Semantic proximity Read ↗

ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity Read ↗

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.Semantic proximity Read ↗

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.Semantic proximity Read ↗

Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.